辉瑞寻求出售其在COVID-19疫苗合作伙伴 BioNTech SE 的全部剩余股权，这场新冠疫情中最具盈利性的合作正逐渐走向尾声。
据知情人士透露，辉瑞计划通过隔夜大宗交易出售约455万份美国存托凭证（ADR），每股定价区间为108至111.70美元。若以价格区间上限计算，此次股权出售将为辉瑞带来约5.08亿美元收益。
两家公司于2020年联手开发COVID-19疫苗，该疫苗在全球创下数百亿美元收入，并在疫情高峰期与美国及欧盟政府达成供应协议。辉瑞对BioNTech的股权投资是合作协议的组成部分。目前双方仍基于BioNTech的专有mRNA技术继续合作开发COVID-19疫苗配方，并共享收益。
制药巨头辉瑞上周历经激烈竞购战，最终以100亿美元收购肥胖症初创企业Metsera Inc.，部分目的是用重磅减肥药替代日益萎缩的新冠业务收入。
随着疫情结束，BioNTech已回归其最初的癌症治疗研发主线，利用积累的资金支持研究。该公司还与百时美施贵宝达成价值高达111亿美元的合作协议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.